Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or above~* Life Expectancy \> 3 months~* Histologically confirmed diagnosis of PTCL~* Patients with transformed CTCL eligible for CHOP regimen~* Measurable disease based on Cheson 2007 criteria~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~Exclusion Criteria:~* Known active Hepatitis B/ Hepatitis C/ HIV infection~* Known, uncontrolled CNS metastases or primary CNS lymphoma~* Deep vein thrombosis diagnosed within 3 months~* Ongoing treatment for pre-existing cardiovascular disease~* Neuropathy Grade 3 or more~* Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation~* Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation~* Prior therapy with HDAC inhibitors (except for CTCL)~* Inadequate hematological, hepatic, or renal function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Finding Phase (Type: EXPERIMENTAL): This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).